Logo image of KNSA

KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Price, Quote, News and Overview

NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD

26.12  -0.58 (-2.17%)

After market: 26.12 0 (0%)

KNSA Quote, Performance and Key Statistics

KINIKSA PHARMACEUTICALS INTE

NASDAQ:KNSA (5/21/2025, 8:11:42 PM)

After market: 26.12 0 (0%)

26.12

-0.58 (-2.17%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High28.56
52 Week Low17.38
Market Cap1.91B
Shares72.97M
Float40.57M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE31.23
Earnings (Next)N/A N/A
IPO05-24 2018-05-24


KNSA short term performance overview.The bars show the price performance of KNSA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

KNSA long term performance overview.The bars show the price performance of KNSA in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of KNSA is 26.12 USD. In the past month the price increased by 25.1%. In the past year, price increased by 37.11%.

KINIKSA PHARMACEUTICALS INTE / KNSA Daily stock chart

KNSA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.7 321.60B
AMGN AMGEN INC 13.07 145.89B
GILD GILEAD SCIENCES INC 13.92 134.11B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.91B
REGN REGENERON PHARMACEUTICALS 13.65 65.28B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 38.06B
ARGX ARGENX SE - ADR 99.65 35.72B
ONC BEIGENE LTD-ADR 5.88 25.49B
BNTX BIONTECH SE-ADR N/A 23.82B
NTRA NATERA INC N/A 20.54B
SMMT SUMMIT THERAPEUTICS INC N/A 18.87B
BIIB BIOGEN INC 8.02 18.58B

About KNSA

Company Profile

KNSA logo image Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.

Company Info

KINIKSA PHARMACEUTICALS INTE

23 Old Bond Street, Floor 3

London HM11 GB

CEO: Sanj K. Patel

Employees: 315

KNSA Company Website

KINIKSA PHARMACEUTICALS INTE / KNSA FAQ

What is the stock price of KINIKSA PHARMACEUTICALS INTE today?

The current stock price of KNSA is 26.12 USD. The price decreased by -2.17% in the last trading session.


What is the ticker symbol for KINIKSA PHARMACEUTICALS INTE stock?

The exchange symbol of KINIKSA PHARMACEUTICALS INTE is KNSA and it is listed on the Nasdaq exchange.


On which exchange is KNSA stock listed?

KNSA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for KINIKSA PHARMACEUTICALS INTE stock?

13 analysts have analysed KNSA and the average price target is 37.3 USD. This implies a price increase of 42.81% is expected in the next year compared to the current price of 26.12. Check the KINIKSA PHARMACEUTICALS INTE stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is KINIKSA PHARMACEUTICALS INTE worth?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a market capitalization of 1.91B USD. This makes KNSA a Small Cap stock.


How many employees does KINIKSA PHARMACEUTICALS INTE have?

KINIKSA PHARMACEUTICALS INTE (KNSA) currently has 315 employees.


What are the support and resistance levels for KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a support level at 25.03 and a resistance level at 27.38. Check the full technical report for a detailed analysis of KNSA support and resistance levels.


Is KINIKSA PHARMACEUTICALS INTE (KNSA) expected to grow?

The Revenue of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 34.22% in the next year. Check the estimates tab for more information on the KNSA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does KINIKSA PHARMACEUTICALS INTE (KNSA) stock pay dividends?

KNSA does not pay a dividend.


What is the Price/Earnings (PE) ratio of KINIKSA PHARMACEUTICALS INTE (KNSA)?

KINIKSA PHARMACEUTICALS INTE (KNSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).


What is the Short Interest ratio of KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

The outstanding short interest for KINIKSA PHARMACEUTICALS INTE (KNSA) is 8.2% of its float. Check the ownership tab for more information on the KNSA short interest.


KNSA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to KNSA. When comparing the yearly performance of all stocks, KNSA is one of the better performing stocks in the market, outperforming 93.54% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

KNSA Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to KNSA. KNSA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KNSA Financial Highlights

Over the last trailing twelve months KNSA reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -327.27% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.44%
ROE -9.85%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%144%
Sales Q2Q%72.54%
EPS 1Y (TTM)-327.27%
Revenue 1Y (TTM)56.6%

KNSA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to KNSA. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 217.89% and a revenue growth 34.22% for KNSA


Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %8.2%
Short Ratio4.9
Analysts
Analysts86.15
Price Target37.3 (42.8%)
EPS Next Y217.89%
Revenue Next Year34.22%